Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is rocketing in the market this morning, trading on gains of more than 35% after announcing positive clinical data. Ultimately, there are three key takeaways that investors should consider here.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
MRNS Stock Gains After Announcing Data
Before we get into the three key takeaways here, let’s take a look at the announcement. In a press release, the company provided top line results from a Phase 2 study.
The study was designed to evaluate intravenous ganaxolone in patients with refractory status epilepticus. During the study, the primary endpoint was met with no patients progressing to IV anesthetics within 24 hours of treatment initiation.
Moreover, MRNS said that ganaxolone had an acceptible safety and tolerability profile across all dose groups and patient populations.
In the release, the company said that not only did it see no escalation to IV anesthetics within the first 24-hours from infusion, there was no need for additional IV AEDs through the follow up period.
The company said that median time to status cessation came in at 5 minutes with positive trends in health outcomes including length of hospital stay. Secondary endpoint measures are being collected as we speak and are expected to be released relatively soon.
In a statement, Dr.Scott Braunstein, CEO at MRNS, had the following to offer:
All patients who received the target dose of ganaxolone, regardless of underlying cause of status, experienced status cessation without progression to additional second line AEDs or third line anesthesia. These data give us confidence in our IV dose selection as we make preparations for advancing into Phase 3 with our first hospital-based ganaxolone indication. I would like to thank the study investigators, patients and their families for participating in this important study.
Key Takeaways To Consider
Ultimately, today’s news proved to be big, with several moving parts. So, what are the parts that investors should be focusing on the closest?
Takeaway #1: The Data Was Positive
First and foremost, the positive data here can’t be ignored. Ultimately, meeting the primary endpoint and maintaining a positive safety and tolarability profile is the important factor here.
Ultimately the trial led to a 100% success rate from an efficacy standpoint with no patients needing IV anesthetics or IV AEDs. If you follow the clinical stage biotechnology space, you know that it’s very rare that 100% of patients in a clinical trial will respond well to any treatment.
Considering the fact that 100% of patients in the trial responded without need for additional IV anesthetics or IV AEDs, the data speaks volumes to validate the work tha Marinus Pharmaceuticals is doing in the space.
Click below to continue reading!